The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of eribulin mesylate (E7389), a novel microtubule targeting chemotherapeutic agent in children with refractory or recurrent solid tumors (excluding CNS), including lymphomas: a Children's Oncology Group Phase 1 Consortium study (ADVL1314).
 
Eric Schafer
Travel, Accommodations, Expenses - Novartis
 
Rachel E. Rau
No Relationships to Disclose
 
Xiaowei Liu
No Relationships to Disclose
 
Charles G. Minard
No Relationships to Disclose
 
David R. D'Adamo
Employment - Eisai
Travel, Accommodations, Expenses - Eisai
 
Rachael Scott
Employment - Eisai
Travel, Accommodations, Expenses - Eisai
 
Larisa Reyderman
Employment - Eisai
Travel, Accommodations, Expenses - Eisai
 
Gresel Minette V. Martinez
Employment - Eisai
Travel, Accommodations, Expenses - Eisai
 
Elizabeth Fox
No Relationships to Disclose
 
Brenda Weigel
Travel, Accommodations, Expenses - Genentech; Lilly/ImClone; Nektar; Roche/Genentech; Roche/Genentech
 
Susan Blaney
Research Funding - Genentech (Inst)